BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31605269)

  • 21. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT).
    Tariq A; McGeorge S; Pearce A; Rhee H; Wood S; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Jun; 40(6):276.e1-276.e9. PubMed ID: 35466037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS; Hicks RJ; Maurer T; Eiber M
    Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET imaging in urology: a rapidly growing successful collaboration.
    Farolfi A; Koschel S; Murphy DG; Fanti S
    Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clear cell renal cell carcinoma with high PSMA uptake.
    Yepes MM; Herrera Ortiz AF; Del Castillo V; Rojas J
    BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38663894
    [No Abstract]   [Full Text] [Related]  

  • 27. 18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
    Marafi F; Sasikumar A; Al-Terki A; Alfeeli M
    Clin Nucl Med; 2020 May; 45(5):377-378. PubMed ID: 32209880
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Currie GM; Trifunovic M; Liu J; Kim S; Gurney H
    J Nucl Med Technol; 2022 Sep; 50(3):282-285. PubMed ID: 34750233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T; Gschwend JE; Eiber M
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in prostate-specific membrane antigen PET of prostate cancer.
    Bouchelouche K; Choyke PL
    Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
    Hofman MS; Iravani A
    PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
    Tolkach Y; Gevensleben H; Bundschuh R; Koyun A; Huber D; Kehrer C; Hecking T; Keyver-Paik MD; Kaiser C; Ahmadzadehfar H; Essler M; Kuhn W; Kristiansen G
    Breast Cancer Res Treat; 2018 Jun; 169(3):447-455. PubMed ID: 29455299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
    Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
    [No Abstract]   [Full Text] [Related]  

  • 37. The utility of radiolabeled PSMA ligands for tumor imaging.
    Shahrokhi P; Masteri Farahani A; Tamaddondar M; Rezazadeh F
    Chem Biol Drug Des; 2022 Jan; 99(1):136-161. PubMed ID: 34472217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
    Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.